FDA Rejects Reproxalap NDA Over Efficacy Concerns
Aldeyra Therapeutics has received a setback in its efforts to bring a new treatment for dry eye disease to market, following a Complete Response Letter (CRL) issued by the U.S. Food and…
Read More...
Read More...
